Current treatment of HIV infection a review simplified: An understanding about hiv infection and anti HIV drugs mechanisam of action

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue SUPPL.1, 2012, Pages 1-14

  Modi, Vishal ^a   Basuri, Tara Shankar ^a   Parmar, Ishvarchandra ^a   Shah, Virag ^a  

^a SSR College of Pharmacy   (India)

Author keywords

Anti HIV drug mechanism; HIV infection

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; DNA VACCINE; EFAVIRENZ; EMIVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; L 708906; L 731,988; LAMIVUDINE; LOPINAVIR; MOZENAVIR; NEIFINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLERIXAFOR; PROTEINASE INHIBITOR; RIBONUCLEASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE; ZLAGEN;

CARCINOGENICITY; CELL FUSION; CELL NUCLEUS; CYTOPLASM; DNA IMMUNIZATION; DRUG MECHANISM; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; MOLECULAR BIOLOGY; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; RESPIRATORY TRACT DISEASE; RETROVIRUS; REVIEW; SKIN DISEASE; VIRION; VIRUS ASSEMBLY; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS RELEASE; VIRUS REPLICATION;

EID: 84858968476     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Beale, J. M. JR. Antiviral Agents, Wilson and Gisvold's Text Book of Organic Medicinal And Pharmaceutical Chemistry, Lipincott Williams & Wilkins, 11th ed., 2004, pp. 367
2. Wagner, E. K.; Hewlett, M. J. (eds): Basic Virology. Malden, MA, Blackwell Science, 1999, pp. 61.
3. Condit, R. C.: Principles of virology. In Knipe, D. M.; Howley, P. M. (eds): Fundamental Virology, Lipincott Williams & Wilkins, 4th ed., 2001, pp. 19.
4. Antiviral Drugs., Rang, H. P.; Dale, M. M.; Ritter, J. M.; Moore, P. K., Text Book of Pharmacology, Elsevier Science, 5th ed., 2003, pp. 657
5. Barre-Sinoussi, F.; Chermann, J. C.;
6. http://www.onlinemarketing-trends.com/2011/02/hiv-and-aids-infection-across-world.html
7. Sexon, A.; Stevens, R. H.; Quan, S. G.; Golde, D. W. Immunologic Characterization of Hairy Cell Leukemias in Continuous Culture. J. Immunol.,1978, 120,777
8. Poiesz, B. J.; Ruscetti, S. W.; Gazdar, A. F.; Bunn, P. A.; Minna, J. D.; Gallo R. C. Detection and Isolation of Type C Retrovirus Particles from Fresh and Cultured Lymphocytes of a Patient with Cutaneous T-Cell Lymphoma. Proc,Natl, Acad,Sci, USA, 1980, 77,7415
9. Baree-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220, 868-871.
10. Fauci, A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science, 1988, 239, 617-622.
11. Piatak, M.; Yang, L. C.; Clark, S. J.; Kappes, J. C.; Luk, K. C.; Hahn, B. H. "High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR". Science. 1993, 259, 1749-1754.
12. Pantaleo, G.; Graziosi, C.; Fuci, A.S. The immunopathogenesis of human immunodeficiency virus infection, N Engl J Med, 1993, 328,327-335
13. Levy, J. A. "HIV pathogenesis and long-term survival". AIDS., 1993, 7, 1401.
14. Gelderblom H.R. Fine structure human immunodeficiciency virus (HIV) and immunolocalization of structural proteins, Virology, 1987, 156(1), 171-176.
15. Mehannna, A. S. Rational of Design of Anti-HIV Drugs, Abraham, D. J., Burger's Text Book of Medicinal Chemistry Drug Discovery, A John Wiley and Sons, Inc., 6th ed, 2003, 5, 461.
16. Wangstaal, F.; Chanda, P. K.; Ghrayeb, J. HIV the eighth gene, AIDS Res. Hum. Retroviruses,1987, 3, 33.
17. www.highred.mcgraw.hill.com
18. Mehannna, A. S. Rational of Design of Anti-HIV Drugs, Abraham, D. J., Burger's Text Book of Medicinal Chemistry Drug Discovery, A John Wiley and Sons, Inc., 2003, 6thed, 5, 461-464.
19. www.aidsinfo.nin.gov
20. Cichocki, M. R. N. The symptoms of HIV. About.com, Medical Review Board
21. Lipsky, J. J. Antiretroviral drugs for AIDS. Lancet, 1996, 348, 800-803
22. Panel on Clinical Practices for Treatment of HIV (2002-09-03). Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
23. www.rkm.com.au.
24. Rohert Guruff, M.; Brown, M.; Gallo, R. C. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature,1985, 316,72.
25. Lasky, L. A. Genome organization and transactivation of the human immunodeficiency virus type 2 Science, 1986, 23, 209.
26. Novertis Research Institute, Current Opinion Investing Drugs, 2001-09-02, 1203-120.
27. Clercq, E. De. New Developments in Anti-HIV Chemotherapy. Curr. Med. Chem., 2001, 8, 1543-1572.
28. Miller, M. D.; Hazuda, D. J. New antiretroviral agents: looking beyond protease and reverse transcriptase.Curr. Opin. Microbiol. 2001, 4, 535-539.
29. Pert, C. B.; Hill, J. M.; Ruff, M. R.; Berman, R. M.; Robey, W. G.; Arthur, L. D.; Ruscetti, F. W.; Farrar, W. L. Octapeptides Deduced from the Neuropeptide Receptor-Like Pattern of Antigen T4 in Brain Potently Inhibit Human Immunodeficiency Virus Receptor Binding and T-Cell Infectivity.Proc. Natl. Acad. Sci. USA, 1986, 83, 9254.
30. Kennedy, P. E.; Moss, B.; Berger, E. A. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology, 1993, 192, 375-379.
31. Mehannna, A. S. Rational of Design of Anti-HIV Drugs, Abraham, D. J., Burger's Text Book of Medicinal Chemistry Drug Discovery, A John Wiley and Sons, Inc., 6th ed, 2003, 5, 467-477.
32. Schols, D.; Este, J. A; Henson, G.; Clercq, E. De. Chemokine receptor binding heterocyclic compounds. Antiviral Res., 1997, 35, 147-156.
33. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizava, Y.; Shiraishi, M.; Aramaki, Y.; Okonogi, K.; Ogava, Y. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA, 1999, 96, 5698-5703.
34. Mayaux, J. F.; Bousseau, A.; Pauwels, R.; Huet, T.; Henin, Y. Derau, N.; Evers, M.; Soler, F.; Poujade, C.; Clercq, E. De. Triterpene Derivatives that Block Entry of Human Immunodeficiency Virus Type 1 Into Cells.Proc. Natl. Acad. Sci. USA, 1994, 91, 3564-3568.
35. Rice, W. G.; Schaeffer, C. A.; Harten, B.; Villinger, F.; South, T. L.; Sunners, M. F.; Henderson, L. E.; Bessjr, J. W.; Arthur, L. O.; Mcderson, J. N.; Orloff, S. F.; Mendeleyev, J.; Kun, E. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature, 1993, 361, 473-475.
36. Turipin, J. A.; Terpening, S. J.; Schaeffer, C. A.; Yu, G.; Glover, G. J.; Felsted, R. L.; Sausville, E. A.; Rice, W. G. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. Virol., 1996, 70, 6180-6189.
37. Witvrouw, M.; Balzarini, J.; Pannecouque, C.; Este, J. A.; Schols, D.; Charapanov, P.; Schmit, J. C.; Debyser, Z.; Clercq, A. De. A disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. Antimicrob. Agents Chemother, 1997, 41, 262-268.
38. Dolin, L. "Antiviral Chemotherapy and Chemoprophylaxis," Science, 1995, 227, 1296.
39. Lin, T. S.; Prusoff, W. H. J. Med. Chem, 1978, 21, 109.
40. Mclaren, C. Review: Didanosine, Antiviral Chem. Chemother, 1991, 2, 321.
41. Chen, C.; Vazquez-Padua, M.; Cheng, Y. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol., 1991, 39, 625.
42. Skalski, V., The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2',3'-dideoxy-3'-thiacytidine. J. Biol. Chem., 1993, 268, 23234.
43. Ho, H. T.; Hitchcock, M. J. M. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus.Antmicrob. Agents Chemother, 1989, 33, 844.
44. Esnouf, R.; Ren, J.; Ross, C. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol., 1995, 2, 303-308
45. Spence, R. A.; Kati, W. M.; Anderson, K. S.; Johnson, K. A. Rohert Guruff, M.; Brown, M.; Gallo, R. C. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Science, 1995, 267, 988-993.
46. Merluzzi, VJ.; Hargrave, KD.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, JC.; Shih, CK.; Eckner, K.; Hattox, S.; Adams, J. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science, 1990, 250, 1411.
47. Romero, D. L. Review: Delavirdin, Drugs Future, 1990, 248, 358.
48. Pedersen, O.; Pedersen, E. Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antiviral Chem. Chemother., 1999, 10, 285.
49. Parniak, M. A.; Arion, D.; Sluis-cremer, M., The M184v Mutation in the Reverse Transcriptase of HIV virus., Antiviral Ther. 2000, 5, 3.
50. Pommier, Y.; Pilon, A. A.; Bajaj, K.; Mazumder, A.; Neamati, N. Pommier Y, Pilon AA, Bajaj K, Mazumder A, Neamati N. HIV-1 integrase as a target for antiviral drugs. Antiviral Chem., Chemother, 1997, 8, 463-483
51. Baba, M.; Okamoto, M.; Makino, M.; Kimura, Y.; Ikeuchi, T.; Sakagichi, T.; Okasmoto, T. Potent and selective inhibition of human immunodeficiency virus type 1transcription by piperazinyloxoquinoline derivatives.Antimicrob. Agents Chemother., 1997, 41, 1250-1255.
52. Turpin, J. A.; Buckheit Jr, R. W.; Derse, D.; Hollingshead, M.; Williamson, K.; Palamone, C.; Osterling, M. C.; Hill, S. A.; Graham, L.; Schaeffer, C. A.; Bu, M.; Huang, M.; Cholody, W. M.; Michejda, C.' Rice, W. G. Inhibition of Acute-, Latent-, and Chronic-Phase Human Immunodeficiency Virus Type 1 (HIV-1) Replication by a Bistriazoloacridone Analog That Selectively Inhibits HIV-1 Transcription.Antimicrob. Agents Chemother., 1998, 42, 487-494.
53. Kempf, D. J. ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. USA. 1995, 92, 2484
54. Wei, X. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995, 373, 117.
55. Kun, E. E. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc., 1995, 117, 1181.
56. Kageyama, S.; Mimoto, T.; Murakawa, Y.; Nomizu, M.; Ford, H.; Shirasaka, Jr. T.; Gulnik, S.; Erickson, J.; Takada, K.; Hayashi, H. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother., 1993, 37, 810.
57. Ho, D. D. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995, 373, 123.
58. Molla, A.; Granneman, G. R.; Sun, E.; Kempf, D. Recent developments in HIV protease inhibitor therapy. J. Antiviral. Res. 1998, 39, 1-23.
59. Lam, P. Y. S.; Jadhav, P. K.; Ru, Y.; Jadhav P. K.; Aldrich, P. E.; Delucca, G. V.; eyermann, C. J.; Chang, C. H.; Emmeett, G.; Holler, E. R.; Daneker, W.F.; Li, L.; Confalone, P. N.; McHugh, R. J.; Han, Q.; Li, L.; Markwalder, J. A.; Seitz, S. P.; Sharpe, T. R.; Bacheler, L. T.; Rayner, M. M.; Klabe, R. M.; Erickson-Viitanen, S.; Hodge, C. Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2' Structure-Activity Relationship, and Molecular Recognition of Cyclic Ureas. J. med.chem. 1996, 39,3514-3525.
60. Bold, G.; Fassler, A.; Capraro, H. G.; Cozens, R.; Klimkait, T.; Lazdins, J.; Mestan, J.; Poncioni, B.; Roser, J.; Stover, D. Tintelnot-Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.; Roussel, S.; Ucci-Stoll, K.; Wyas, D.; Lang, M. New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical Development. J. med.chem. 1998, 41,3387-3407.
61. Hoetelmans, R. M. W. Novel compound in preclinical/early clinical development of the NNRTIs (Tipranavir), Current. Opin. Anti infect. Invest. Drugs. 1999,1, 241-45.
62. Altreman, M.; Bjorsn, M.; Mulman, A.; Classon, B.; Kvarnstrom, I.; Danielson, H.; Markgren, P. O.; Nillroth, U.; Unge, T.; Halberg, A.; Samuelsson, B. Design and Synthesis of New Potent C2 -Symmetric HIV-1 Protease Inhibitors. Use of L-Mannaric Acid as a Peptidomimetic Scaffold. J. med. Chem., 1998, 41, 3782-92.